#United States #Cambridge #Marengo Therapeutics #Dr. Mikael Dolsten #Dr. Josep Tabernero

Marengo Therapeutics Strengthens its Leadership Team

Marengo Therapeutics, Inc., a clinical-stage biotechnology firm specializing in innovative precision immunotherapy solutions, has announced pivotal additions to its management structure, aiming to bolster its strategic direction and clinical development initiatives. The company has officially welcomed Dr. Mikael Dolsten to its Board of Directors and Dr. Josep Tabernero to its Scientific Advisory Board (SAB). This move signifies a crucial step towards advancing Marengo's mission to develop groundbreaking therapies for various cancer types.

Leading Experts Join Forces

Dr. Mikael Dolsten, an esteemed figure in pharmaceutical R&D, previously served as the Chief Scientific Officer and President of Worldwide Research, Development, and Medical at Pfizer. With over 16 years of leadership experience, Dr. Dolsten's insights and expertise will be instrumental as Marengo aims to expand its clinical pipeline effectively. His storied career includes significant contributions to the advancement of innovative medicines across various therapeutic areas, notably leading Pfizer’s efforts during the COVID-19 pandemic and shaping the future of their extensive oncology portfolio.

Under Dr. Dolsten's stewardship, Pfizer successfully realized over 36 drug approvals, with an emphasis on oncology. His extensive track record in biopharma is complemented by advisory roles in major investment groups, solidifying his status as a key authority in this field. Dr. Dolsten expressed his enthusiasm for joining Marengo at a time when the firm is poised for significant growth and innovation in its clinical investigations.

On the other hand, Dr. Josep Tabernero, an internationally recognized leader in medical oncology, has lent his expertise to this initiative as a member of the SAB. As the Head of the Medical Oncology Department and Director at the Vall d'Hebron Institute of Oncology in Barcelona, Dr. Tabernero has made remarkable contributions to the oncology research community, particularly concerning gastrointestinal cancers. He has played notable roles in various esteemed oncological societies, such as serving as the President of the European Society for Medical Oncology (ESMO).

Pioneering Clinical Development Strategies

Marengo's CEO, Zhen Su, has expressed profound confidence in the capabilities of Dr. Dolsten and Dr. Tabernero. The company's strategic direction is geared towards advancing its proprietary immunotherapy candidates, including invikafusp alfa, which targets various tumor types such as colorectal cancer (CRC), gastroesophageal junction (GEJ) tumors, and non-small cell lung cancer (NSCLC).

Dr. Tabernero remarked on the promising clinical signals identified in ongoing studies involving invikafusp alfa, citing encouraging outcomes in crucial cancer categories. His expertise will play a vital role in advising Marengo as it seeks to navigate the complexities of clinical trial development and the approval landscape.

The Path Forward for Marengo Therapeutics

Marengo Therapeutics is more than just a biotech company; it's a pioneer in the field of immunotherapy, focusing on developing novel therapies based on a unique understanding of T cell interactions and their potential to combat cancer. The company's proprietary platforms, including Selective T Cell Activation Repertoire (STAR), embody its commitment to precision and effectiveness in immunotherapy.

Dr. Dolsten’s arrival is expected to enhance Marengo's capability to innovate in its drug discoveries and to scale operations efficiently. With such heavyweight experts on board, Marengo is well-positioned to redefine cancer treatment paradigms and bring targeted therapies to market that promise improved outcomes for patients across a spectrum of cancer types.

In conclusion, the recent strategic appointments at Marengo Therapeutics represent a significant infusion of knowledge and experience into the organization, crucial for navigating the challenging landscape of biotechnology and pharmaceutical development. As the company embarks on its next chapter, the contributions of Dr. Dolsten and Dr. Tabernero will undoubtedly be pivotal in shaping its trajectory.